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SUMMARY 
  
In this work we designed two nanoparticle-enzyme (NP-enzyme) systems: 
one for medical and one for industrial applications. 
The first NP-enzyme system, thought for medical purpose, especially for 
cancer therapy, is represented by the NP-DAAO system.  
Briefly, D-amino acid oxidase (DAAO) is an enzyme that generates reactive 
oxygen species (ROS) and it is believed of having potential uses as a novel 
therapeutic molecule if internalized by cancer cells or just localized on their 
plasma membrane. When conjugated onto iron oxide nanoparticles (NP-
DAAO), the enzyme can be magnetically directed to targeted locations with 
an increased efficacy. Subsequently, ROS production can be initiated by 
injection of DAAO substrate D-alanine inducing apoptosis of cells 
surrounding the NP-DAAO complex. Here we described a platform for 
optimal bioconjugation using monodisperse γ-Fe2O3 NPs (~10 nm) resulted 
in high DAAO loading (24 U/mg NPs), stable NP-DAAO dispersions and more 
than 90% enzymatic activity recovery, which is retained when NP-DAAO are 
exposed to human serum. Lastly, we proved its efficacy in killing different 
tumor cell lines (SKOV-3, U87, and HCT-116) compared to the free enzyme. 
The second NPs-enzyme system designed in this study is conceived for 
industrial application. This NPs-system is composed of Fe3O4 NPs conjugated 
to L-aspartate oxidase (LASPO).  
This NP-LASPO system will combine the catalytic activity of LASPO to resolve 
racemic solution of D,L-aspartate with the possibility to recover and reuse 
the system once the reaction in the bioreactor is over. Thanks to its 
magnetic feature, it will be possible to obtain pure end products without the 
enzyme contamination. In industrial applications this NP-LASPO system will 
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enable a simpler, faster and cheaper resolution of racemic mixtures of D,L-
Aspartate. In this study, we optimized an existing protocol for the LASPO 
immobilization on NPs changing the parameters of the conjugation reaction. 
Finally, we improved the NP-LASPO conjugation process by increasing the 
enzymatic activity recovery from 37.5% up to 134.6%.  
Since the application of these NP-enzyme systems, as well as the NPs, can be 
employed for biomedical and industrial applications, it is necessary to assess 
their possible toxicity. 
In the last part of this work, we started a study on the toxicity of magnetic 
NPs. We focused on the toxicity of Cobalt, Iron, Nickel zerovalent NPs and 
the potential influence on the Adipose-derived Stem Cells (ASCs) 
differentiation process.  
A population of hASCs was effectively isolated and characterized by flow 
cytometry: its stemness was proved by the positivity to CD44, CD90, CD105 
and HLA-A,B,C and negativity to CD45 and HLA-DR. Afterwards, the 
cytotoxicity of CoNPs, FeNPs and NiNPs was assayed on hASCs: CoNPs and 
NiNPs exert a dose and time dependent cytotoxic effect which is higher 
compared to FeNPs. Finally, the possible hASCs Adipogenic differentiation 
induced by CoNPs was evaluated. The morphological analysis pointed out 
that both CoNPs and CoCl2 were able to speed up the differentiation 
process. These are preliminary results and we need to investigate in more 
detail if this process is due to CoNPs or Co2+ ions or both these components. 
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I.I   BACKGROUND 
 
I.1   Nanotechnology, Nanomaterials and Nanoparticles 
In the last years, nanomaterials (NMs) have caught the interest of research 
communities all around the world. The Official Journal of the European 
Union defined Nanomaterial as “a natural, incidental or manufactured 
material containing particles, in an unbound state or as an aggregate or as 
an agglomerate and where, for 50% or more of the particles in the number 
size distribution, one or more external dimensions is in the size range 1 nm-
100 nm”1. NMs are distinguished by the number of dimensions between the 
size range of 1 nm-100 nm: nanofilms (one dimension), nanofibers and 
nanotubes (two dimensions) and nanoparticles (three dimensions)2. 
Among all the NMs, nanoparticles (NPs) are the most popular. The origin of 
NPs is various and they can be grouped into two main classes: natural and 
anthropogenic NPs (Tab. 1).  
 
Tab. 1: The main sources of nanoparticles3. 
 
 
I.I   BACKGROUND 
8 
The field that deals with the design, synthesis and characterization of NMs 
and nanostructures is called Nanotechnology. One of its purposes is to 
create new products with properties and functions that differ from the ones 
of their bulk materials. Such properties are attributable to the increased 
ratio between the surface area and the number, per given mass, of the NPs; 
this fact allows a greater chemical reactivity, a higher electrical 
resistance/conductivity and, potentially, a more pronounced biological 
activity3. NMs are now widespread from industrial applications, such as 
catalyst4, sensors5 and photovoltaic devices6, to agriculture7,8, food safety9,10 
and cosmetics11,12. Some of the numerous nanoparticles applications13 are 
reported in Fig.1. 
 
Fig. 1: Overview of the nanoparticle applications13. 
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I.2   Magnetic nanoparticles 
Besides their small size and different chemical activity from their bulk 
materials, NPs are very interesting also because of their magnetic 
properties. These particular properties, acquired when the particles size 
diminishes to the nano level, are due to an increased role of the surface 
spins. It was observed that some non-magnetic elements, such as Pd and Pt, 
present magnetic-like properties at the nano-size14. 
From the beginning of the new millennium, magnetic NMs are considered to 
overcome some technical limits like data recording and storage15–17. NMs 
helped also to update existing biomedical techniques such as magnetic 
resonance imaging (MRI), which exploits magnetic NPs as contrast agents to 
diagnosis18,19, and more and more often for both diagnosis and therapy as 
theragnostic agents20–22. 
One of the most versatile groups of magnetic nanoparticles that can be 
employed in almost every application field is the one of the Iron Oxide 
Nanoparticles (IONPs). Among them, Superparamagnetic IONPs (SPIONs) are 
the leaders for biomedical applications mainly due to their biocompatibility 
and the large possibility of customization23,24.  
SPIONs present an iron oxide core that can be coated by either inorganic 
and/or organic materials. The most noticeable aspect that renders SPIONs a 
suitable candidate for numerous applications is their inducible high 
magnetization when exposed to an externally applied magnetic field: that 
allows heating or targeting them to the area of interest, for instance a 
tissue25. However, when exposed to the oxygen present in the air, these NPs 
can be oxidized resulting in a partial loss of their magnetic behaviour. Hence, 
it is necessary to create specific coatings to stabilize NPs to avoid their 
surface oxidation26. The coating molecules often merely act as a barrier to 
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protect the NPs against external agents; otherwise, it happens that they may 
drastically affect the electronic properties of the NPs. Therefore, the 
modification of the NP surface by covering their surface atoms with specific 
molecules plays a crucial role in the stabilization of the system by minimizing 
their energy14.  
 
I.3   Surface Modification of NPs 
During the last decade researchers were pushed to study new structures of 
material and inorganic/organic compounds able to ensure more and/or new 
performance characteristics. These efforts resulted in several types of NP 
architectures with different core/shell arrangements, especially for IONP24 
(Fig.2) which meet the needs of almost every application. 
Up to now, there is a very high number of organic and inorganic compounds 
for NP functionalization and coating. These compounds can be used to 
improve the NP biocompatibility and/or chemical stability but also to tune 
their dispersibility and solubility in water or other solvents. Especially for 
IONPs, these agents endow to iron oxide new physicochemical properties, 
such as magneto-optical, magnetic-electrical properties and magnetic-
thermal properties26.  
Coating compounds can be divided in: 
? Organic coatings like small organic molecules or surfactants, 
biomolecules and polymers. 
? Inorganic coatings like silica layer, metal/non-metal elements and 
metal oxide/sulfide. 
The protecting shells are often used not only to stabilize the NPs but also as 
a platform to further other functionalization processes in which, for 
instance, the NP core is covered by an inorganic coating and then again 
I.I   BACKGROUND 
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functionalized with an organic one. These multiple functionalization 
processes are essentials to build up personalized NPs: that allows designing 
the suitable final NP for the task planned for it. 
 
 
Fig.2: General types of IONP arrangements with molecules, polymers and inorganic 
chemicals (not in scale)24. 
 
Another helpful method to group IONPs for biotechnological application is 
to cluster them depending on the functional end-group they present on 
their surface. Some of the most used coating/functionalization compounds 
for IONPs are reported in Tab.2.  
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Tab.2: Polymers and organic molecules (sorted by functional group) typically used 
for the primary coating and/or stabilization of IONPs. 
Chemical end-group Compound 
-OH 
-Polyethylene glycol 
-Dextran 
-Polyvinylalcohol 
-COOH 
-Polyacrylic acid 
-Carboxymethylcellulose 
-Polyethylene glycol with terminal -COOH 
-Alginate 
-Polymethacrylic acid 
-Citrate 
-NH2 
-Chitosan 
-Polyethylenimine 
-Poly(L-lysine) 
-Polyethylene glycol with terminal -NH2 
-Ethylenamine 
-Aminosilane 
 
One of the most used functionalization compounds is the silane-like group. 
The hydrolysis/condensation reactions of these compounds lead to the 
formation of silane coating all around the NPs with their functional end-
group oriented towards the external environment. The easy-controlled 
reaction, the large number of commercially available silane coupling agents 
and the well-documented chemistry represent three of the many 
advantages of the silane-like compounds; in addition, their high surfaces 
coverage and their strong binding, ensured by the functional groups, lead to 
a very stable core/shell structure. Among the silane compounds, the APTES 
(3-Aminopropyltriethoxysilane) is of great interest27 (Fig.3). 
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Fig.3: APTES structure. The APTES hydrolysis and condensation in water form a 
silane polymer that reacts with NPs. 
 
When APTES is dissolved in water, with a little amount of ethanol, 
hydrolyzes and condensates to form a silane polymer. During the hydrolysis 
reaction, the alkoxide groups (–OC2H5) are replaced by hydroxyl groups (-
OH) to form reactive silanol groups. These silanol groups condense one with 
the other to produce siloxane bonds (Si–O–Si) and in the meantime with the 
-OH present on the NPs surface to produce NP-O-Si bonds. Thus, the APTES 
amino group (-NH2) remains free to bind other molecules28. 
Regarding the biomedical applications, in the past 30 years many 
biomolecules were conjugated to the functionalized NPs such as DNA, RNA 
and oligonucleotides (i.e. ssDNA/RNA, dsDNA/RNA), peptides, enzymes, 
carbohydrates, antibodies, tumor markers, fluorescent dyes, polymers (i.e., 
PEGs), drugs and so on29 (Fig.4). Finally, one of the actual aims is to create 
innovative multifunctional NPs able to carry on their surface several 
biomolecules with different functions (i.e., theragnostic agents). 
I.I   BACKGROUND 
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Fig 4: Schematic representation of a multifunctional NP able to act as a carrier of 
various biological molecules29. 
 
I.4   NP Interactions with Biological World 
When NPs are spread into the surrounding environment, they are subject to 
an uncountable number of interactions with various chemical and physical 
agents that will sign their fate. It is evident how the aquatic and terrestrial 
environments are potentially endangered. Humic substance present in 
water and soil, also known as natural organic matter (NOM), is the one that 
most readily interact with the NPs released into the environment30. 
In order to prevent the damage to the ecosystems, we must be aware of the 
specific features of the NP released into the environment: each 
chemical/physical variable of the NP itself, or the media in which is exposed, 
can influence its integrity and finally the ability to interact with other 
molecules. Indeed, whilst molecules are metabolized in short or at least in 
long term exposure, non-stabilized NPs can rapidly form aggregates and, in 
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long term exposure, are able to dissolve themselves in ions or to lose their 
stabilizing coating31 (Fig.5). 
 
 
Fig.5: Inside the organism the fate of molecules is mainly signed by degradation 
and metabolism processes. Regarding NPs,it is difficult to predict it because of their 
agglomeration behaviour that affects the NP mobility, biodistribution, and 
clearance. Even stabilized NPs during long-term exposure in biological media can 
become unstable through chemical modification or loss of surface functionality31. 
 
There are many ways by which NPs may enter the human body31: inhalation, 
ingestion, penetration through the skin and injection into the blood stream. 
Once inside the body, NPs interact with the biomolecules present in 
biological fluids (interstitial fluid between cells, lymph or blood) resulting in 
the adsorption by most of them onto the NP surface in the so called 
“biomolecular corona”. The structure and composition of that “biomolecular 
corona” depend on the nature of the physiological environment (blood, 
interstitial fluid, cell cytoplasm, etc.), the physicochemical properties of the 
NP (size, shape, composition, surface functionalization and charges) and the 
duration of exposure32. For instance, proteins followed by a small amount of 
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lipids mainly characterize the biomolecular corona composition of NPs 
exposed to blood plasma. This protein absorption is guided by the binding 
affinities between the NP and the proteins: that binding affinities can be 
very strong and stable leading to the formation of the “hard” corona or 
weak and loosely with the formation of the “soft” corona (Fig.6). 
 
 
Fig.6: Simplified illustration of a NP with soft and hard protein corona. The 
exchange time and lifetime of the proteins in the corona is determined by their 
rate of adsorption (Ka) and desorption (Kd). The different protein composition 
forming the hard/soft corona often results in a very complex system of proteins. 
 
Reassuming, the biomolecular corona is a highly variable platform of 
adsorbed biomolecules onto the NP surface: it represents, at the end, the 
peculiar biological "fingerprint" of each NP. As a consequence, the specific 
NP protein corona is responsible to interface towards the receptors located 
on the cell plasma membrane. This process is very important during the NPs 
cell uptake from the bloodstream and the following redistribution from one 
cellular compartment to another33. Once NPs are injected into the 
bloodstream they are immediately coated with blood plasma proteins 
enabling an opsonisation process that renders them more susceptible to be 
identified and removed by phagocytic cells of the reticuloendothelial system 
I.I   BACKGROUND 
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(RES): that represents one of the most arduous hurdles to overcome for 
biomedical application. Hence, to elude the RES, the NP surfaces can be 
coated with natural or synthetic polymers allowing a prolonged circulation 
in the biological fluids34. A new and innovative approach, inspired by the 
concept of molecular biomimetism, is based on the self-recognition of 
homologous erythrocytes, red blood cells (RBCs), to bypass the RES 
checkpoints. This approach exploits the great variety of proteins residing on 
the RBCs membrane35,36 to coat on the NPs surface making it similar to 
natural RBCs37: the main advantage is the possibility to escape the RES 
allowing a prolonged systemic circulation38–40 (Fig.7). 
The results obtained through the RBCs membrane coating for NPs 
functionalization have demonstrated their validity to connect the properties 
of natural cell membrane components with those of NPs. 
 
 
Fig.7: (A) Simplified preparation procedure of RBC membrane-camouflaged Fe3O4 
NPs (Fe3O4@RBC NPs). (B) Uncoated Fe3O4 NPs are quickly removed by the RES 
(e.g., peripatetic macrophages and macrophage-rich organs: liver and spleen). (C) 
Fe3O4@RBC NPs can escape the RES uptake41. 
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As previously reported, the NPs can enter the human body by different ways 
and eventually interact directly with cells. Thus, it is possible that NPs can 
cross the cell plasma membrane mainly by five different pathways: 
clathrin/caveolae-mediated endocytosis42,43, phagocytosis44, 
macropinocytosis45, pinocytosis44 and non-endocytic way46,47. Afterwards 
the internal vesicular transits, NPs can be exocyted via three pathways: 
lysosome secretion48, vesicle-related secretion49, and non-vesicle-related 
secretion42,49. These NPs endocytosis and exocytosis mechanisms are briefly 
resumed in Fig.8. 
 
 
Fig. 8: Scheme of the endocytosis and exocytosis patterns of nanoparticles42. 
MVBs, multivesicular bodies. 
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Endocytosis, intracellular distribution and exocytosis are either modulated 
by the physicochemical properties of NPs such as size, shape, surface charge 
and functionalization33, but also by cell-specific parameters such as cell type 
or cell cycle phase50. During the NP intracellular transit/storage it can 
happens that, depending on the NP feature51,52, a part or the whole NP, 
including its core, the surface layer and the biomolecular corona, may be 
modified, removed or metabolized. The main mechanism through which the 
NPs are removed from the body is via the renal clearance pathway53. 
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I.5   NP Safety and Toxicity 
The NPs toxicity depends on their physicochemical features: size, 
composition, reactivity, mobility, stability, surface charge and chemistry, 
agglomeration/aggregation, storage medium and time54,55.  
As mentioned in the previous section, NPs can enter the body via different 
ways, reach and flow into the blood stream and, at the end, get into the 
cells. Moreover, it has been observed that NPs are also able to overcome 
biological barriers and to biodistribute among different organs based on 
their physicochemical nature56 (Fig. 9).  
 
 
Fig.9 The size (a), shape (b) and surface charge (c) dictate the NPs biodistribution 
among different organs including the lungs, liver, spleen and kidneys56. 
 
Once inside the cell, NPs generally exert toxicity through two different, but 
sometime correlated, mechanisms: the generation of reactive oxygen 
species (ROS) and the NP dissolution into toxic ions57,58. Either the 
mechanisms are responsible for several cytotoxic effects such as DNA 
damaging and mitochondrial membrane disruption57,59–61. 
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Iron 
Many studies report IONPs as highly biocompatible with very low toxicity62–
67. IONPs of 8.9 nm width assayed on two human epithelial cell lines (A549, 
Caco2) and murine fibroblasts (Balb/c 3T3) showed a very low cytotoxicity 
only at the highest concentration tested (100 µg/mL)64. In another study a 
similar cytotoxic results were observed exposing A549 cells to 80 µg/mL 
IONPs65. Furthermore, also some IONP surface coatings are helpful to 
reduce the NPs toxicity and promote cellular uptake66. 
An often ignored or underestimated aspect of IONPs is the surface 
passivation which incredibly reduces the NP toxicity by erasing the surface 
reactivity67. 
Although, some recent reviews place the doubt on IONPs safety because of 
their contradictory results68–70, demanding more detailed analysis to assess 
deeper: 
- in vitro aspects such as the cellular effects, ROS generation, ions 
release and genetic effects.  
-  in vivo aspects such as the toxicokinetics, acute toxicity, 
genotoxicity, neurotoxicity, immunotoxicity and reproductive 
toxicity. 
These future studies will be helpful to fill the main gaps of knowledge in the 
IONP safety and toxicity fields. 
 
Silver 
Silver NPs (AgNPs) are the best example of NP toxicity related to ROS 
generation and ions release. It was demonstrated that small-size (15 nm) 
Silver NPs (AgNPs) generate 10 fold more ROS than large-size AgNPs (30-55 
nm), that makes smaller NPs more toxic compared to larger ones 71. Another 
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study proved that the size-dependent cytotoxicity of AgNPs in human lungs 
cells was due to the Ag ions release from the NPs into the culture media72. 
This study supported the theory of the so called ‘Trojan horse effect’ by 
which the NPs cellular uptake increases the concentration of toxic ions 
following the natural or enhanced by lysosome acid pH NP dissolution73 
(Fig.10). Other researchers observed that different-shaped AgNPs affect the 
cells viability in a different way74. Finally AgNPs were proved to induce 
inflammation, genotoxicity, cytotoxicity and developmental toxicity57. 
 
 
Fig. 10: Schematic representation of the Lysosome-Enhanced Trojan Horse effect 
(LETH effect) in which the active internalization mechanisms of NPs leads to an 
intracellular increase of toxic ions if compared to endocytosis-free NPs73. 
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I.6   NP Applications 
There are many fields in which NP applications thrive and most of them are 
listed in Fig.1. In biotechnology, a new branch of nanotechnology called 
nanobiotechnology has arisen to deals with the NP study and applications 
combined to biological world. The nanobiotechnology research aims to 
develop simple, safe and useful NP applications especially for biomedicine 
and industry. 
 
Industrial Applications 
NPs are employed in almost every industry fields from electronics to 
chemicals, from engineering to energy75. 
In construction industry, NPs are used to improve the mechanical features 
of many materials. For instance, the concrete can increase its compressive 
strength by more than 15% when nickel NPs are added. Another example 
are silica NPs which are employed as an antireflection coating on windows 
allowing to control the exterior light and to reduce the energy loss following 
air conditioning76. 
Among all these applications, in industry-related nanobiotechnology, the 
enzyme biocatalysis has elicited much interest. In particular NPs were seen 
as a solution to overcome the limitations of the enzyme-efficiency-
determining factors77. 
 
Enzyme Biocatalysis 
Enzymes are the most efficient and versatile catalyst78. They often win the 
challenge against chemical catalyst by offering more competitive processes.  
Chemical and pharmaceutical industries use the enzymes biocatalysis to 
produce various chemical and biological substances because enzyme-based 
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processes usually lead to a reduction of reaction steps and, consequently, to 
a saving of time and waste79. 
The specific chemoselectivity, regioselectivity and stereoselectivity of 
enzymes demonstrate their superiority in the industrial production of 
enantiomerically pure compounds80. Besides organic synthesis, the enzyme 
biocatalysis is also helpful in many areas of research81, including 
immunoassays82 and substrate sensing83. 
However, despite the great potential in industrial applications, the use of 
free enzymes presents several drawbacks such as: thermal instability, 
activity inhibition, protease digestion, denaturing agents sensitivity and the 
impossibility of separating/reusing the enzyme at the end of a reaction. To 
overcome such limitations, researchers attempted parallel approaches like 
the screening of enzymes from natural sources, random mutations and 
immobilization on different substrates84–86.  
In this view, the enzyme immobilization for industrial applications aims to87: 
- improve the enzyme overall stability  
- increase the volume loading of specific biocatalyst  
- simplify the biocatalyst recycling and the downstream processing 
Immobilized enzymes have the advantages of a larger pH working range, an 
improved thermal stability and an easier separation from the bioreactor88. 
Other advantages are the enhanced enzyme activity, the modification of 
substrate selectivity/enantioselectivity and the multi-enzyme reaction89–91. 
Among all the various scaffolds used for enzyme immobilization, NPs 
provide interesting features (minimal diffusional limitation, maximum 
surface area and high effective enzyme loading) to be tailored combined 
with those of enzyme91,92. Such “nanobiocatalyst” can load a much higher 
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amount of enzyme, enhancing significantly the mass transfer efficiency, if 
compared to enzyme immobilized on micrometric supports93.  
During the last years, magnetic NPs have received increasing attention due 
to their magnetic characteristics which facilitate their recovery by using a 
magnetic field94,95. IONPs, for instance, have aroused great interest in 
biodiesel production96 and food processing because of their biocompatibility 
and cheapness 97. 
 
Medical Applications 
The application of NPs in medicine is called Nanomedicine98. The NPs 
currently used in nanomedicine include liposomes, polymeric micelles, 
inorganic and polymeric NPs, nanorods and quantum dots. The medical 
applications of NPs range from diagnosis to drug/gene delivery, from 
therapy to tissue engineering29,99,100. As mentioned before, the customizable 
characteristics of NPs allow them to cross biological barriers such as the 
blood brain barrier (BBB) that is impermeable to almost every drugs but not 
to the ones conjugated to NPs101–103.  
Once injected into the blood stream, the NPs have to be attracted to the 
target tissue in order to carry out their tasks. 
There are three ways to localize IONPs into the cancer tissue 21: 
- Passive Targeting: this strategy takes advantage of the peculiar 
physiology of tumor in respect of normal tissue (Fig.11 A). The 
passive targeting requires NPs with a diameter below the 200 nm 
able to accumulate into the tumor tissues exploiting their enhanced 
permeability and retention (EPR). Tumors often present an enhanced 
permeability of vessels with a little lymphatic drainage, leading to a 
passive accumulation and retention of NPs with prolonged 
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circulation times (EPR effect). The disadvantage of this strategy is 
that it is possible to be applied only in certain types of tumors. 
- Active Biological Targeting: this procedure involves the NP surface 
functionalization with specific biomarkers able to recognise the 
tumors by targeting tumor cells (Fig.11 A). These biomarkers include 
small organic molecules, peptides, proteins and antibodies that are 
complementary to unique receptors, present or overexpressed, on 
the external surface of tumor cells plasma membrane. However, the 
synthesis of these targeting agents is expensive and needs high 
knowledge in chemistry. 
- Active Magnetic Targeting: this technique enables the NPs 
accumulation by applying external magnetic field on the target site 
(Fig.11 B). Unfortunately, since the magnetic field strength decreases 
with the distance from the magnet, the efficacy of this kind of 
targeting is limited to the tissues close to the body's surface. 
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Fig.11: Different modalities of IONPs tumor targeting: passive and active biological 
targeting104 (A) and active magnetic targeting105 (B). 
 
Unfortunately, despite the mechanism of targeting, about the 99% of all 
administered NPs are sequestered and/or eliminated by the RES and the 
renal system53. During the last 30 years, only few strides were made to solve 
this problem suggesting to give priority on the NP delivery studies before 
undergoing to the clinical testing53. Hence, the NP targeting and delivery to 
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malignant tissue (e.g. tumours) still remain a great challenge in 
nanomedicine.  
 
Theragnosis 
Among the different medical applications, the possibility given by magnetic 
NPs to combine diagnosis with therapy has led to the development of 
theranostic agents106. In this regard, gadolinium-based NPs, that were used 
as positive contrast agents for MRI, now may act as therapeutic agent for 
neutron capture therapy or radiosensitization18. Beside gadolinium-based 
NPs, the IONPs are widely used as theranostic agents thanks to their 
magnetic features and the availability of many functionalization 
biomolecules allowing to pursue different aims24,107,108. Especially for in vivo 
treatments, IONPs magnetic properties can be employed in three main 
groups of applications105: drug delivery, MRI contrast agents, 
hyperthermic/photoresponsive agents. For cancer theranostic applications 
of IONPs these three groups are often enclosed in a single and multitasking 
system20 as shown in Fig.12. IONPs can act as an effective anticancer loading 
platform for targeted drug delivery (TDD) to carrier a wide range of 
molecules109–111. Furthermore, the IONPs magnetic aspects make them 
perfect for hyperthermia and thermoablation105,112. In these two techniques, 
the heat produced by IONPs when exposed to an external alternating 
magnetic field is used to induce necrosis in cancer cells. Together with 
hyperthermia, IONPs find also application as a photo-thermal therapeutic 
agent (PTA) in NIR photothermal therapy for efficient ablation of tumors113. 
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Fig.12: Example of magnetic nanoparticle for theranostic applications20,114 
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II.1   NP-Enzyme system for cancer therapy: NP-DAAO 
The first part of this work proposes an improvement of the magnetic 
nanoparticle-enzyme system (NP-DAAO) preparation previously proposed by 
Bava et al.115 and subsequently upgraded by Cappellini et al.116. This 
magnetic nanoparticle-enzyme system, thought for cancer therapy, utilizes 
magnetic IONPs conjugated with the enzyme D-amino acid oxidase (DAAO) 
to produce reactive oxygen species directly in a tumor, with the aim of 
reducing side effects and improving the patient’s life quality. 
What we tried to do in this study is to combine the advantages of IONPs 
with those of DAAO, minimizing their disadvantages such as the low 
preservation of DAAO activity and storage instability at 4°C. Thanks to the 
magnetic characteristics of the IONPs and their ability to cross biological 
barriers103, it will be possible to localize this system, after injection into the 
blood stream, directly into the cancer mass with the help of an external 
magnetic field given by a powerful magnet (Fig.12 b). Once there, the 
injection of D-Alanine (one of the DAAO substrates) will produces H2O2 that 
will cause the death of the surrounding tumorigenic cells via apoptosis. In 
order to understand whether these particles can be used for nanomedicine 
purposes, it is important to optimize their synthetic route and to evaluate 
their toxicity on different cell lines. 
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DAAO 
DAAO (EC 1.4.3.3) is a FAD-dependent enzyme that catalyzes with a high 
stereospecificity the oxidative deamination of D-amino acids to give α-keto 
acids and ammonia. Then oxygen, the terminal redox acceptor, reoxidizes 
the FAD cofactor previously reduced giving hydrogen peroxide117(Fig.13). 
Putative DAAO genes are present in all kingdoms but not in the plants, 
among which Chlorella vulgaris represents the only exception117.  
 
 
Fig. 13: Scheme of the DAAO reaction with D-amino acids to give α-keto acids, 
ammonia and H2O2117. 
 
DAAO in Prokaryotes 
In prokaryotes, it has been found a similar DAAO enzyme called D-amino 
acid dehydrogenase (DAAdH EC 1.4.99.1). DAAdH is a flavoenzyme that 
oxidizes neutral D-amino acids, in particular D-Ala, into the corresponding α-
keto acids. The DAAdH of E. coli is a heterodimer with two different 
subunits: the smaller one of about 45-kDa contains the FAD as coenzyme 
that transfers the two electrons received from the substrate to the sulfur-
iron centre of the larger one of 55-kDa that eventually reduces the 
coenzyme Q. One interesting feature of DAAdH is that its oxidation 
processes do not involve the O2 reduction to avoid a dangerous ROS 
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overproduction. The DAAdH is located in the periphery and is considered 
associated with the bacterial inner cell membrane. In bacteria, its known 
roles are mainly two: the first regards the energetic metabolism and the 
second involves the prevention of the inhibitory effect given by 
overconcentration of D-amino acids on bacterial growth117.  
 
DAAO in Eukaryotes 
In eukaryotic organism, DAAO is a peroxixomal enzyme involved in the D-
amino acids metabolism. Its peroxisomal location allows an efficient 
scavenging of the H2O2 produced during the oxidation reaction of D-amino 
acids. The D-amino acids may come from endogenous or exogenous sources 
and, once oxidized in the corresponding α-ketoacids, they can be used 
directly for the cell energetic metabolism or converted into L-amino acids 
and integrated into the proteins. However, if the D-amino acids are present 
in high concentration (>1 mM), the DAAO metabolic ability is not fast 
enough to prevent their accumulation into the tissues: that causes an 
extensive and serious damage e.g. the suppression of synthesis of some 
important enzymes and retardation of growth118. A very important DAAO 
role is to maintain physiological D-serine levels in the different brain tissues. 
D-serine is one of the most important regulators of the N-methyl-D-
aspartate (NMDA) receptors whose dysfunction, due to erroneous DAAO 
gene expression, is one of the multiple causes that lead to schizophrenia 
disease117. Furthermore, a low DAAO activity was found in kidney and liver 
tumor cells if compared to healthy ones: that parameter could result useful 
for the early detection of tumors in these organs119. 
Among all the eukaryotic DAAO, the one from the yeast Rhodotorula gracilis 
(RgDAAO) represents a very interesting protein because of its high turnover 
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rate and FAD binding stability120. RgDAAO is a quite stable homodimer in 
which each subunit binds non-covalently the FAD cofactor. The primary 
structure of the single monomer consists in 368 amino acids corresponding 
to 40076 Da117. The secondary structure is composed by 11 α-helices and 13 
β-sheets. At the N-terminus, there is the FAD-binding domain consisting in a 
βαβ motif that envelops the FAD and buries it inside the protein. The C-
terminus, involved in the head-tail monomer dimerization, contains a 
unique loop of 21 amino acids that is not found in other known DAAO 
sequences. The dimerization occurs through the electrostatic interactions 
between the positively charged residues on the βF5-βF6 loop of one 
monomer and the negatively charged ones belonging to the α-helices I3’ 
and I3’’ of the other monomer117 (Fig. 14) leading to a dimer of 80 kDa.  
 
Fig. 14: RgDAAO homodimer with the typical head-to-tail interaction of the two 
monomers. The thick arrows identify the βF5-βF6 loop whilst the thin arrows 
identify the α-helices αI3’ and αI3’’ 117. 
 
The RgDAAO active site is situated in a cavity delimited by two couples of β-
strands: the first couple (I4 and I8) is bent around the isoalloxazine ring of 
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the flavin whilst the second one (I5 and I6) is situated close to the substrate-
binding site. The flavin constitutes the “bottom” of the cavity. All the β-
strands present in the structure of the active site have an antiparallel 
orientation and are connected to each other by hydrogen bond which 
stabilize and stiffen the structure121. 
 
Industrial application of DAAO 
Industrial applications of the RgDAAO concern primarily the production of 
the 7-(5-oxoadipoamido)cephalosporanic (7-ACA) acid through the 
enzymatic deamination of the cephalosporin C. The 7-ACA is then used as a 
starting molecule to produce more than 50 semi-synthetic 
cephalosporins122. Since the production of 7-ACA without DAAO is very 
laborious and expensive, the use of this enzyme permits to save money and 
time allowing a better purification of the final products if bound to magnetic 
NPs120. Besides the 7-ACA production, DAAO is also used to resolve racemic 
solution of D,L-amino acids, obtaining optically pure solution of L-amino 
acids123. 
 
Medical applications of DAAO 
In the medical field, the DAAO is used for the production of α-keto acids, 
which are consequently administered as food additive to treat patients with 
chronic uremia124. A new and emerging DAAO medical application concerns 
cancer therapy by exploiting its H2O2 production following D-amino acids 
oxidation. The H2O2-induced apoptosis125 is made possible by different ROS 
generating enzymes like glucose oxidase (GO), xanthine oxidase (XO) and 
DAAO. The use of exogenous GO is tricky and can‘t be modulated because of 
the widespread and uncontrollable presence of its substrates (oxygen and 
I.II   NP SYSTEMS FOR BIOMEDICAL AND INDUSTRIAL APPLICATIONS 
35 
glucose)126. Similarly, XO, because of its enzymatic promiscuity, can’t control 
its ROS production since it has a wide range of ubiquitous substrates127. On 
the contrary, DAAO is the optimal candidate to perform the H2O2-induced 
apoptosis of cancer cells because of the very low presence of D-amino acids 
in humans and the absolute stereoselectivity of RgDAAO. With RgDAAO it is 
possible to regulate strictly the ROS production by the exogenous 
administration of D-amino acids127. 
 
II.2   NP-Enzyme system for industry: NP-LASPO 
The second part of this work focuses on the development of a magnetic 
nanoparticle-enzyme system designed for industrial application. This system 
utilizes a commercial Fe3O4 NPs (IONPs) that, once functionalized with APTES 
(IO-APTES), are conjugated with the L-aspartate oxidase (LASPO) giving the 
IO-APTES-LASPO system (NP-LASPO). This NP-LASPO system will combine 
the catalytic activity of LASPO to resolve racemic solution of D,L-aspartate 
with the possibility to recover and reuse the system when the reaction in 
the bioreactor is over. Thanks to its magnetic feature, it will be possible to 
obtain pure end products without the enzyme contamination. In industrial 
applications that NP-LASPO system will enable a simpler, faster and cheaper 
resolution of racemic mixtures of D,L-Aspartate. In this study the protocol 
for the LASPO immobilization on NP-APTES was optimized. 
 
LASPO 
LASPO (EC 1.4.3.16) is a prokaryotic and FAD-dependent enzyme that 
catalyzes with a high stereospecificity the oxidative deamination of L-
aspartate and L-asparagine to give α-keto acids and ammonia. Then, 
similarly to DAAO, the oxygen reoxidizes the FAD cofactor previously 
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reduced giving hydrogen peroxide. In prokaryotes, LASPO has a fundamental 
role in the de novo biosynthesis of nicotinamide adenine dinucleotide 
(NAD+) by catalyzing the first reaction step. In vivo, the iminosuccinate 
produced by using L-aspartate as substrate is then condensed with 
dihydroxyacetone phosphate resulting in the production of quinolinate and, 
eventually, NAD+. In vitro, LASPO is able to use both O2 and fumarate in FAD 
re-oxidation, allowing to perform its catalytic reaction in aerobiosis and 
anaerobiosis: under aerobic condition, the LASPO oxidizes L-aspartate to 
iminosuccinate, which is then hydrolyzed to oxaloacetate through a non-
enzymatic pathway128(Fig. 15). 
 
 
Fig. 15: Catalytic reaction of LASPO: the L-aspartate is oxidized to iminosuccinate 
followed by a nonenzymatically hydrolyzation to oxaloacetate128. 
 
Among all the studied LASPO, the one isolated from the thermophilic 
microorganism Sulfolobus tokodaii (StLASPO) is of potential interest for 
industrial applications. StLASPO is a monomeric (52 kDa) enzyme formed by 
a single polypeptide chain composed by 472 residues organized into three 
distinct folding domains: a FAD-binding domain, a capping domain, and a C-
terminal domain129 (Fig.16). One of the most interesting and attractive 
features of StLASPO is the high thermal stability: StLASPO is stable up to 80 
°C where no remarkable changes in its activity were observed during an 
incubation of 400 min at pH 7.5. Besides the high thermal stability and high 
temperature optimum, StLASPO arouses interest also because of the stable 
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activity in a wide range of pH (7.0-10.0), the tight interaction with FAD and 
the weak inhibition caused by D-aspartate and by the final product(s) (i.e., 
iminosuccinate or oxaloacetate)130. 
 
 
Fig. 16: StLASPO overall structure: the FAD-binding, capping and C-terminal 
domains are shown respectively in red, cyan and green. The FAD cofactor is 
represented as a stick model in yellow with oxygen and nitrogen atoms in red and 
blue, respectively129. 
 
Recombinant StLASPO was efficiently used for the resolution of a racemic 
mixture of D,L-aspartate and, thanks to its high stability, the enzyme was 
effectively reused for one more bioconversion cycle obtaining the same 
conversion yield130. Moreover, StLASPO was successfully immobilized on 
various supports reaching in terms of activity about 50-100% of yield131. 
These results suggest a very interesting perspective for the StLASPO 
conjugation on different supports (i.e. magnetic NPs) aiming to improve the 
enzyme qualities. 
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Stem cells play an important role in several processes such as recovery of 
functional absences in diseases, homeostasis of healthy tissues, 
regeneration of damaged tissues and, unfortunately, in tumor formation. 
Therefore, it is evident how dangerous could be the perturbation of the 
stem cell homeostasis. When NPs enter, intentionally or not, the body may 
encounter stem cells and upset their physiology, for instance, unbalancing 
their differentiation process. Although several studies have demonstrated 
the toxic effects of NPs on cultured cell lines, up to now there are no clear 
data describing the overall molecular changes induced by them. 
In this third and last part of my work I present a preliminary study of the 
toxicity and influence of Cobalt, Iron, Nickel zerovalent NPs on the 
differentiation process of Adipose-derived Stem Cells (ASCs).  
 
III.1   Adipose Stem Cells (ASCs) 
ASCs are a subgroup of Mesenchimal Stem Cells (MSCs) derived from 
adipose tissue firstly isolated and described as a new source of adult stem 
cells in 2001 by Zuk et al.132. Since the discovery, ASCs attracted more and 
more interest especially in regenerative medicine because of their peculiar 
features such as: 
? The abundance of adipose tissue from which they are extracted that 
is easily recoverable through liposuction, a non-invasive surgery, as 
well as in the context of surgical interventions in which adipose 
tissue is removed due to aesthetic and/or functional reasons. 
? The high differentiation potential among MSCs. 
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? The low immunogenicity that renders them suitable for 
allotransplant.  
? The simplicity in setting ASCs cultures without the need of specific 
and expensive compounds that otherwise can affect their 
differentiation processes. 
? The overcome of ethical issues still present for the use of Embryonic 
Stem Cells (ESCs). 
Several studies proved the multipotency of ASCs (Fig.17). In vitro it is 
possible to induce the ASCs differentiation mainly by culturing cells in 
culture media supplemented with specific growth factors; indeed, by using 
the right mixture of growth factors, ASCs are able to differentiate following 
the mesodermal lineage into adipocytes, chondrocytes, osteoblasts and 
myocytes133,134. Furthermore, many studies demonstrated the potential 
ability of ASCs to transdifferentiate toward cell lines of both the ectodermal 
and the endodermal lineages like neurons, motor neurons, Schwann cells, 
keratinocytes, hepatocytes and pancreatic cells135.  
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Fig.17: Schematic resume of ASCs multipotency. 
 
Moreover, ASCs can support hematopoiesis, angiogenesis and 
vascularization, by participating in the blood vessels formation136 and/or 
differentiating toward endothelial cells137. 
Another distinctive characteristic of ASCs is the lack of HLA-DR expression 
that allows them to evade the host's immune system. ASCs can inhibit the 
production of pro-inflammatory cytokines whilst stimulating the generation 
of anti-inflammatory IL-10 cytokine138. Their immunosuppressive properties 
result also from the production of prostaglandin E2 and 2,3 dioxygenase 
indole139. Hence, ASCs are able to protect against organ rejection and 
prevent from the Graft-Versus-Host-Disease (GVHD) after allogeneic stem 
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cell transplantation140. Thanks to their immune “stealth” abilities, ASCs 
could be a very interesting opportunity for therapeutic purposes in 
allogeneic transplantation in which it will be possible to collect from a 
suitable donor and standardize different ready-to-use ASCs cell lines141. 
Finally, ASCs are preferred to the golden standard of the Bone Marrow-
derived Stem Cells (BMSCs) because of the easier and safer sample 
collection from the donor, the more abundance of stem cells up to 500 
fold142, the simple cell culture with a rapid cell growth143. 
 
III.2   Cobalt, Iron, Nickel zerovalent NPs 
Cobalt, Iron and Nickel are three transition metals belonging to the VIIIb 
group of the periodic table. The choice to investigate the zerovalent NPs of 
Co, Fe and Ni aims to fill some knowledge gaps related to the present lack of 
the literature data about the toxicity and biological interactions of these 
three elements in the form of NPs. 
 
Cobalt NPs 
Cobalt NPs (CoNPs) are one of the most promising materials for 
nanotechnological applications ranging in different industrial sectors such as 
the production of pigments, catalysts and sensors, as well in 
electrochemistry, magnetism, memory storage, magnetic fluids144–146. CoNPs 
are used also in nanomedicine as a highly sensitive contrast agent in 
MRI147,148. However, it was proved that CoNPs aggregates are toxic on 
different cell lines: that toxicity was mainly due to Co ion dissolution from 
the CoNPs149. 
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Iron NPs 
Iron NPs (FeNPs) are widely used for the groundwater and soil remediation 
from pollutants such as phenanthrene and chlorinated ethanes/ethenes150 
as well as heavy metals151. Nevertheless, to reduce the environmental risks 
linked to the FeNPs dispersion, it is of use their immobilization on supports 
such as alginate beads or activated carbon; this strategy allows to retrieve 
and store the NPs146,152. However, many concerns remain about their fate 
and toxicity153,154. 
 
Nickel NPs 
Nickel NPs (NiNPs) find application in modern industry as catalysts, sensors 
and in electronics155,156. However, their usage is creating concerns due to 
the potential risk associated to the toxicity of Ni-derived compounds that 
may be released from NiNPs into the environment. The International Agency 
for Research on Cancer (IARC) has classified the Ni-derived compounds as 
"carcinogenic to humans" (Group 1) while metallic Ni as "possible 
carcinogenic to humans" (Group 2B) with genotoxic and mutagenic 
activities157. Finally, NiNPs were proved capable of inducing lung epithelial 
and respiratory pathologies in human158,159, embryotoxicity in zebrafis160 
and spermiotoxicity in Ciona intestinalis161. 
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DAAO enzyme 
The D-Amino Acid Oxidase (DAAO) used in this work is the wild type from 
Rhodotorula gracilis that was produced as recombinant proteins in E. coli 
and purified as stated in Fantinato et al.162. The final stock DAAO solutions 
were equilibrated in 50 mM potassium phosphate buffer at pH 7.5, 2 mM 
EDTA, 10% v/v glycerol and 5 mM 2-mercaptoethanol. MilliQ Ultrapure 
Water System (Millipore, MA, USA) was used. The DAAO enzyme was 
provided by the laboratory of Prof. Loredano Pollegioni of the Biotechnology 
and Life Sciences Department of Università degli Studi dell'Insubria, Varese. 
 
IONPs 
Two different types of Iron Oxide Nanoparticles (IONPs) were used: 
1. The first type was γ-Fe2O3 synthetized de novo (dIONPs) following a 
protocol based on Bee et al.163 and Geppert et al.164. The detailed 
synthesis process is reported below.  
2. The second type was a commercial Fe3O4 nanopowder (cIONPs) 
acquired from Sigma (n.cat: 637106) with the particle size < 50 nm. 
These Fe3O4 NPs were the same utilized by Bava et al.115 and 
Cappellini et al.113. 
The synthesis of dIONPs was performed in an Erlenmeyer flask positioned 
on a heating plate with a magnetic stirrer. Because of the risk of production 
of nitrous gases in the heating steps, the synthesis was conducted under a 
working fume-hood. The here described synthesis will yield approximately 
50 mL of aqueous dIONPs dispersion with a total iron concentration of 500-
700 mM. Nevertheless, it is possible to up- or downscale this method. 
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Preparation of dIONPs: 
1. Weigh in 8.89 g FeCl3 * 6 H2O (Sigma-Aldrich n. cat: 31232) and 3.28 
g FeCl2 * 4 H2O (Sigma-Aldrich n. cat: 44939) and dissolve it in 380 mL 
H2O (in a 500 mL Erlenmeyer flask) on a magnetic stirrer for 30 min. 
While stirring add slowly 1.5 mL of 37% HCl to dissolve iron salts 
completely. 
2. Add slowly and under strong stirring 25 mL of 25% NH4OH to iron 
solution: a black precipitate will appear. Stir for additional 10 min. 
3. Remove flask from magnetic stirrer and let particles precipitate by 
placing a permanent magnet (NdFeB-magnet) under the flask and 
wait until all the NPs are collected to the bottom (that happens after 
10-20 min.). Be careful working with NdFeB-magnet since their 
magnetic field is very strong. 
4. Remove the supernatant (aqueous media) by decantation and wash 
twice the NPs with 100 mL of H2O MilliQ, leaving them 10 min on 
magnetic stirrer for each washing. During the last washing steps, 
transfer the suspension into a smaller Erlenmeyer flask (100 mL). 
5. After the transfer, add 40 mL of 2 M HNO3 and heat up to 90 °C for a 
5 min. The suspension will turn colour from black to dark brown. 
6. Isolate particles again with the magnet and add 60 mL of 0.34 M 
solution of Fe(NO3)3 * 9 H2O (Sigma-Aldrich n. cat: 216828). Heat up 
to 90 °C and stir for 30 min. 
7. Cool down to RT and remove supernatant (NdFeB-magnet). 
8. Add 50 mL of H2O (can be more) on the particles and stir properly. 
The particles will now “dissolve” leading to a magnetic fluid 
containing a well dispersion of iron oxide nanoparticles. 
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9. Filter NPs through 0.2 µm syringe filters for removal of larger 
aggregates. If dispersion cannot be filtered well, add more water to 
dilute the ferrofluid and use new filter. 
10. Pipette into a glass bottle and store at 4 °C. If needed the IONPs 
solution can be dialyzed to remove any Iron salts still present after 
the last steps. 
 
IO-APTES NPs (NP-APTES) 
IONPs were functionalized with APTES (Sigma n. cat: A3648) following two 
methods depending on the type of IONPs used. 
 
NP-APTES from de novo synthesis (dNP-APTES) 
Since dIONPs were suspended in aqueous media, the corresponding of 150 
mg of NPs was added to 1 mL of a solution composed by 975.4 µL of EtOH 
and 24.6 µL of APTES. The right amount of APTES was calculated from the 
total NPs surface area to have enough APTES to coat each NP whilst EtOH 
was added up to the volume of 1 mL. The reaction was maintained under 
mechanical stirring for 1 h at RT and for 1 h at 90 °C. Then, the synthetized 
dNP-APTES were washed three times with H2O MilliQ by centrifugation 5 
minutes at 10000 x g and resuspended in H2O MilliQ by ultrasonication. The 
centrifugation washing passages were necessary because the collection with 
the magnet used for the Sigma NPs would have required too much time.  
 
NP-APTES from Sigma NPs (cNP-APTES) 
150 mg of cIONPs were ultrasonicated with Ultrasonic Cleaner M S3 (Soltec, 
Milan, Italy) in 10 ml of H2O MilliQ for 20 min. To start the functionalization 
reaction, a solution of 5 mL APTES (2% w/v) in H2O MilliQ was added to NPs 
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and maintained under mechanical stirring for 5 h at 50 °C, according to del 
Campo et al.27. The Fe3O4-APTES (cNP-APTES) were then separated from 
unbound APTES by a commercial parallelepiped neodymium magnet 
(Webcraft GmbH, Uster, Switzerland; Ni-Cu-Ni plated; magnetization: N45; 
size: 30x30x15 mm), washed with 5 mL of H2O MilliQ until pH 7 was 
reached. Afterwards, cNP-APTES were washed twice with 5 mL of EtOH and 
resuspended in 10 mL of EtOH. Then, they were ultrasonicated for 20 min 
and left in EtOH overnight. The day after, cNP-APTES were collected with the 
magnet and washed twice with 10 mL of H2O MilliQ, ultrasonicated for 30 
min and left at room temperature for 1 h. Hence, the water was removed 
and the cNP-APTES were dried at 50°C overnight. 
 
IO-APTES-DAAO NPs (NP-DAAO) 
NP-APTES NPs were conjugated with different amount of RgDAAO 
depending on the free surface area presented by 4 mg of NP-APTES. 
 
NP-DAAO from dNP-APTES (dNP-DAAO) 
For 1 mL of reaction, 4 mg of dNP-APTES were activated in NaPPi buffer 5 
mM pH 8.5 by adding EDC (1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride, Sigma n.cat: 03450) and NHS (N-hydroxysulfosuccinimide, 
Sigma, n.cat: 130672) in the ratio 3:2 w/w. Then, 1786 µg of DAAO were 
added and NaPPi buffer 5 mM pH 8.5 up to a final reaction volume of 1 mL. 
The reaction was carried out for 4 h at 4 °C using a rotating plate tube 
stirrer. Eventually, the dNP-DAAO were collected by placing the sample on a 
magnet in ice (~4 °C) and washed twice with 1ml of NaPPi buffer 5 mM pH 
8.5. The supernatant was stored for further analysis.  
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The choice of the suitable amount of DAAO for the conjugation was done 
starting from the fixed ratio used for cNP-DAAO between the µg of DAAO 
per the total surface area given by 4 mg of cNP-APTES, and then moving to 
the surface saturation by increasing the amount of enzyme. The total 
surface area of 4 mg NP-APTES was calculated from the average particle 
diameter, assuming spherical particles, by DLS analysis. For 4 mg of dNP-
APTES were successfully loaded up to 1786 µg of DAAO. 
 
NP-DAAO from cNP-APTES (cNP-DAAO) 
According to the method used by Cappellini et al.116, 4 mg of cNP-APTES 
were suspended by ultrasonication for 15 min with the same activation 
solution of EDC/NHS solution as previously described. Then, 250 µg of DAAO 
were added and NaPPi buffer 5 mM pH 8.5 up to a final reaction volume of 1 
mL. The reaction was carried out for 4 h at 4 °C using a rotating plate tube 
stirrer. Subsequently, cNP-DAAO were collected through the magnet and 
washed twice with 1 mL of NaPPi 5 mM pH 8.5. The supernatant was stored 
for further analysis. The 250 µg of DAAO were chosen as the maximum 
loading capability per 4 mg of cNP-APTES as reported by Cappellini et al.116. 
A general and schematic representation of the whole NP-DAAO system 
formation is resumed in Fig. 18. 
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Fig. 18:  Schematic representation of the NP-DAAO system formation process. 
 
Transmission Electron Microscopy (TEM) Pictures and Analysis 
dIONPs, dNP-APTES and dNP-DAAO were observed with a JEOL 1010 
electron microscope (JEOL, Tokyo, Japan). Each sample was diluted in H2O 
MilliQ and deposed onto a 200 nm mesh Formvar/carbon-coated copper 
grid. The NPs size distribution graphs were carried out by counting 100 NPs 
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per picture. Statistical analysis was performed using one way ANOVA with 
Scheffè test among the three groups of NPs. 
 
Dynamic Light Scattering (DLS) Analysis 
NP size measurements by DLS were carried out in H2O MilliQ. NP dispersions 
were prepared by diluting the NP stock (25 mg/mL) to the required 
concentration (0.075 mg/mL). Measurements were performed at 25 °C using 
a Malvern Zetasizer Nano ZS90 (Worcestershire, UK). DLS results are 
reported as the average of at least 3 runs, each containing 13 individual 
measurements.  
 
Zeta Potential (Z-pot) Analysis 
Zeta potential (Z-pot) measurements were performed with the samples 
diluted to 0.075 mg/mL in 0.1% PBS at 25 °C using a Malvern Zetasizer Nano 
ZS90 (Worcestershire, UK). 
 
Differential Centrifugal Sedimentation (DCS) Analysis 
DCS experiments were performed with a CPS Disc Centrifuge DC24000. The 
analyzer measures the particle size distribution using centrifugal 
sedimentation within an optically clear spinning disk filled with fluid. The 
measurements were conducted in a sucrose gradient of 8−24% in H2O MilliQ 
at 19000 rpm of speed. The concentration of the samples analyzed was 
0.075 mg/mL. 
 
Spectra Analysis 
The amount of DAAO bound on the NP surface was determined by 
considering the difference between the starting amount of DAAO and the 
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protein recovered in the supernatant at the end of the conjugation reaction. 
The quantification of conjugated DAAO was performed using the extinction 
coefficient at 455 nm (~12.6 mM-1cm-1) and an UV-Vis V-560 
Spectrophotometer (JASCO, MD, USA). 
 
dNP-DAAO enzyme activity assay 
The NP-DAAO activity was determined by measuring the absorbance 
increase accompanying the H2O2-induced oxidation of O-dianisidine. One 
DAAO unit corresponds to the amount of enzyme that converts 1 µmol of 
substrate per min at 25°C and at 0.253mM oxygen concentration.  
The standard assay mixture contained 890 µL of 100 mM D-Ala in NaPPi 
buffer 100 mM pH 8.5, 100 µL 3.2 mg/mL O-dianisidine in H2O MilliQ, 10 µL 
of 0.4 mg/mL horseradish peroxidase in NaPPi buffer 100 mM pH 8.5 and, 
eventually, 10 µL of 0.4 mg/mL NP-DAAO in the same buffer. The reaction 
starts by adding the enzyme and the absorbance increase is monitored at 
440 nm (~13 mM-1cm-1) for 1 min at 25 °C using an UV-Vis Jasco V-560 
Spectrophotometer (JASCO, MD, USA). 
 
dNP-DAAO Yield and Activity Recovery 
The immobilization yield was calculated as the percentage of the ratio 
between the Immobilized enzymatic Activity of DAAO on NP-DAAO (IA) and 
the Starting enzymatic Activity of DAAO added to the conjugation reaction 
(SA): ????????? ? ???? ? ??? 
The IA refers to the difference between the SA and the DAAO enzymatic 
activity retained by the supernatant at the end of conjugation reaction. 
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Finally, to describe how much enzymatic activity is retained by the 
immobilized DAAO, it was calculated the Activity Recovery as the 
percentage of the ratio between the Observed enzymatic Activity of the 
DAAO loaded on NP-DAAO (OA) and the SA: ????????????????????? ? ???? ?? ??? 
This parameter gives an overall idea of the success of the total 
immobilization process.  
 
dNP-DAAO storage stability 
The dNP-DAAO were stored at 4 °C in NaPPi buffer 5 mM pH 8.5 and assayed 
after 1, 2, 4 and 8 months. Three different dNP-DAAO batches were 
analyzed and the results were normalized against the dNP-DAAO activity 
recorded the day of the DAAO conjugation to dNP-APTES.  
 
dNP-DAAO activity in presence of human serum 
The dNP-DAAO activity was investigated at different time (5, 30, 60 min.), 
temperature (20, 25, 30, 37 °C) and with or without the addition of human 
Serum (hS) at the final concentration of 10%.  
The incubation solution with 10% hS was prepared by adding: 890 μL of 
NaPPi buffer 100 mM pH 8.5, 100 μL of hS and 10 μL of dNP-DAAO (stock 
sol. 4 mg/mL). The dNP-DAAO activity was determined as reported 
previously. 
The 10% hS concentration was chosen on the basis of pilot experiments 
carried out with dNP-DAAO NPs incubated at 37 °C within the range 0.1-50% 
of hS.  
Statistical analysis was performed using one way ANOVA with Scheffè test 
among the three groups of NPs. 
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Cell culture  
Four different cell lines were used to evaluate the dNP-DAAO in vitro 
cytotoxicity and capability to kill human cancer cells. As a tumor model, 
three different human cell lines were used: SKOV-3 from ovary 
adenocarcinoma, U87 from glioblastoma and HCT116 from colorectal 
carcinoma. As non-tumor cell line, the hASCs (human Adipose-derived Stem 
Cells) cell line was used. 
RPMI1640 medium was employed to maintain SKOV-3 and HCT116 cell lines 
as adherent cells while DMEM medium was used for U87 cell line and a 1:1 
DMEM/DMEM-F12 medium for hASCs. Every cell line was incubated at 37 °C 
in a humidified 5% CO2 atmosphere. RPMI1640, DMEM and DMEM/DMEM-
F12 medium were supplemented with 10% fetal bovine serum, 1% L-
Glutamine and 1% penicillin/streptomycin solution; DMEM medium was 
supplemented with also 1% sodium pyruvate and DMEM/DMEM-F12 
medium with 0.1% gentamicin. Cells were passaged as needed using a 
solution at 0.25% trypsin–EDTA.  
 
Cell viability test 
Cell viability was determined as ATP content by using the CellTiter-Glo 
Luminescent Cell Viability Assay (Promega) according to the manufacturer’s 
instruction. In detail, 200 μL of cell suspension containing 10000 cells were 
seeded into 96-well plates and cultivated for 24 h at 37 °C in 5% CO2 to 
equilibrate and become attached prior the treatment. Then, cells were 
exposed for 24 h to 3.5, 7 and 14 mU of free DAAO and dNP-DAAO with or 
without 1 mM of D-Alanine (one of the DAAO substrates). The choice of this 
specific range of Units was based on the current literature115. 
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Following the treatment, the plates were equilibrated for 30 min at room 
temperature and after the medium was replaced with 100 μL of new one 
plus 100 μL of CellTiter-Glo Reagent was then added to each well. Plates 
were shaken for 2 min and left at room temperature for 10 min to 
equilibrate the luminescent signal that eventually was recorded by using the 
Infinite F200 plate reader (Tecan Group, Männedorf, Switzerland). For all 
the cell lines, the experiments were performed in triplicate and repeated 
three times. Cell viability, expressed as ATP content, was normalized against 
control values.  
 
Comparison between dNP-DAAO and cNP-DAAO 
The whole dNP-DAAO system (dIONPs, dNP-APTES and dNP-DAAO) was then 
compared to one obtained from the Cappellini et al116 procedure that 
represents the updated NP-DAAO system in literature (cNP-DAAO). Hence, 
cIONPs, cNP-APTES and cNP-APTES were synthesized and characterized by 
DLS and DCS analysis to highlight the differences among dNP-DAAO and 
cNP-DAAO. For DLS and DCS analysis, each sample of the cNP-DAAO system 
was processed alike the one of the dNP-DAAO system. 
Furthermore, the yield, the activity recovery and the intrinsic cytotoxicity of 
the dNP-DAAO were compared to cNP-DAAO to have an overall outlook of 
any improvements. Regarding the intrinsic cytotoxicity comparison, it was 
used as a model the SKOV-3 cell line. 
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Samples characterization by TEM, DLS, DCS and Zeta-potential analysis 
In this work, different techniques were used for a full NPs characterization. 
TEM characterization is necessary to obtain a direct particles imaging on 
dried NPs and to provide a quantitative measure of the NPs size, size 
distribution and morphology. 
TEM pictures and analysis (Fig. 21) show that dIONPs (Fig. 19a), dNP-APTES 
(Fig. 19b) and dNP-DAAO (Fig. 19c) possess an average size, expressed in 
nm, of respectively 8.5, 10.3 and 11.0. These results suggest a slight increase 
but statistically significant (P < 0.002) from the bare NPs towards the dNP-
APTES. However, any statistical significance is observed among dNP-APTES 
and dNP-DAAO (P < 0.341). These results might be explained by the 
formation of dNP-DAAO aggregates during the DAAO conjugation reaction 
that cannot be well distinguished with TEM analysis. 
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Fig. 19: TEM analysis dIONPs (a), dNP-APTES (b) and dNP-DAAO (c). The NPs size is 
expressed in nm as the average size ± standard deviation. 100 counts for each 
sample were measured. 
 
DLS characterization is used to get information about the hydrodynamic 
radius of NPs dispersed in a liquid solution. The DLS analysis allows to 
observe the changes occurred in the NP size and size distribution when 
exposed to different solvents. 
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 The DLS characterization analysis (Fig. 20a) reports a diameter of about 38 
nm for the dIONPs and about 47 nm for the dNP-APTES. After conjugation 
with the DAAO enzyme, dNP-DAAO acquire a wider diameter of 
approximately 185 nm. Although the low PDI of both dIONP and dNP-APTES 
indicates the presence of monodisperse particles, the high PDI of dNP-DAAO 
suggests the probable formation of aggregates. 
DCS characterization exploits the NP density and sedimentation time to 
calculate the NP size. This technique is very sensible and can detect more NP 
subpopulations within the same NP solution, highlighting also the presence 
of agglomerates and or aggregates. 
The DCS analysis (Fig. 20b) of dIONPs results in a NPs average diameter of 
about 34.5 nm. As expected, the surface functionalization with APTES and 
DAAO results in a change of the particle sedimentation time. The dNP-APTES 
and dNP-DAAO have respectively an apparent size of 24 nm and 76 nm: this 
is due to a change in the sample density as also reported in other 
publications165–167.  The narrow peaks present in each of the sample tested 
indicate a well-defined population of particles.  
Under the best experimental condition, the still presence of dNP-DAAO 
aggregates is probably due to a slight aggregation process during DLS and 
DCS analysis. However, further analysis will be conducted to better 
understand the dNP-DAAO behavior in aqueous buffers. 
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Fig. 20:  DLS (a) and DCS (b) analysis of dIONPs, dNP-APTES NPs and dNP-DAAO 
NPs. The NPs size is expressed in nm as the average size ± standard deviation. The 
Polydispersity index is from cumulant fitting. 
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The Z-pot represents a very important analysis to record the surface charge 
of NPs. This analysis is to know the charge changes on the NP surface 
following the functionalization reaction. 
The Z-potential analysis (Fig.21) shows a negative Z-pot for both dIONPs and 
dNP-DAAO of respectively -35.6 and -11.3 mV whilst dNP-APTES is positive 
at 9.8 mV. These measurements were performed in 0.1% PBS because the 
ones in H2O MilliQ did not possess a suitable grade of salinity to allow stable 
and reproducible results. The negative Z-pot of the dNP-DAAO suggests a 
lower toxicity profile if compared to positively charged NPs54,55. 
Furthermore, it was proved that slightly negatively charged NPs might be 
highly up taken by tumor due to their prolonged blood circulation167. These 
results are very promising for the ultimate goal of using dNP-DAAO in cancer 
therapy. 
 
 
Fig. 21:  Z-potential of dIONPs, dNP-APTES and dNP-DAAO. The Z-pot is expressed 
in mV as the average Z-pot ± standard deviation. 
 
In Tab. 3 all the results of the analysis performed for the dNP-DAAO system 
characterization are resumed .  
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Tab. 3: dNP-DAAO system characterization by TEM, DLS, DCS and Z-pot analysis. 
 
 
DAAO conjugation to dNP-APTES  
The DAAO enzyme was successfully conjugated up to 446 µg per mg of dNP-
APTES with a maximum of 1786 µg per reaction (4 mg of dNP-APTES).  
As shown in Tab. 4, the dNP-DAAO conjugation Yield and the Activity 
recovery were stable respectively at the 100% and 91%. Since it was 
employed a stock RgDAAO solution of about 59 U/mg, the units of enzyme 
loaded were about 24 U per mg of dNP-APTES up to 96 U per whole 
reaction. 
 
Tab. 4: dNP-DAAO system features. Amount of enzyme loaded per mg of dNP-
APTES; yield and activity recovery expressed in percentage; enzymatic Units (U) per 
mg of dNP-DAAO. 
 
  
Sample dIONPs dNP-APTES dNP-DAAO 
size (d.nm)TEM 8.5 ± 3.5 10.3 ± 3.4 11.0 ± 3.5
Z-Average (d.nm)DLS 38.3 ± 0.4 47 ± 0.2 185.1 ± 6.1
PDIDLS 0.191 0.123 0.279
Peak (d.nm)DCS 34.5 ± 0.2 24.0 ± 0.2 76.0 ± 2.0
Z Potential (mV) -35.6 ± 0.6 9,8 ± 0.06 -11.3 ± 0.06
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dNP-DAAO storage stability 
The dNP-DAAO activity was checked up to 8 months (Fig. 22). The dNP-
DAAO activity shows a very low but constant decrease that after 8 months 
of storage at 4 °C reaches about the 16% activity loss. These results permit 
to store the entire batch on dNP-DAAO at 4 °C for at least 8 months without 
a great loss of enzymatic activity of the DAAO loaded. Compared to one of 
the previous NP-DAAO system115 the storage stability is improved greatly 
going from the 20% of activity loss at two months to 6% and not more the 
17% after 8 months. 
 
 
Fig. 22:  dNP-DAAO storage stability from the day of the DAAO conjugation up to 8 
months. The dNP-DAAO was stored at at 4 °C in NaPPi buffer 5 mM pH 8.5. Over 
each column is reported the percentage of retained activity normalized to Day 1 
(shown as time “0”). 
 
  
II.II   RESULTS AND DISCUSSION 
62 
dNP-DAAO thermal stability in presence of hS   
As Fig. 23 suggests, the DAAO and dNP-DAAO enzymatic activity decreases 
with the increase of either the time and the temperature of incubation. 
From 20 to 30 °C no significant differences were observed in term of activity 
loss between the DAAO and dNP-DAAO. However, when incubated at 37 °C 
for 1 h, the dNP-DAAO retain about the 80% more of enzymatic activity 
compared to the DAAO alone (P < 0.0005). The enzymatic activity is an index 
of the overall enzymatic stability, therefore we can assume that the DAAO 
loaded on dNP-DAAO possess an enhanced thermal stability when 
compared to the DAAO alone.  
Since the dNP-DAAO, thought for cancer therapy, have to be injected 
intravenously to perform its activity, it was assessed the influence of human 
Serum (hS) on the dNP-DAAO enzymatic activity.  
 
 
Fig. 23: Thermal stability of DAAO and dNP-DAAO during 5, 30, 60 minutes of 
incubation with/without 10 % human Serum (hS) at different temperatures (20, 25, 
30 and 37 °C). 
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Interestingly, the incubation with hS 10% retains the enzymatic activity of 
dNP-DAAO as well as of DAAO. The results show that especially at 37 °C 
after 1 h of incubation, the hS positively affect the DAAO activity retention 
(P < 0.022) but not the dNP-DAAO (P < 0.24). 
The results obtained by Z-pot analysis and by the dNP-DAAO activity assay 
when incubated with hS are preliminary but promising: they can indicate the 
NPs possible long-term stability into biological fluids, allowing their 
accumulation in a specific area of the body. Human serum plays an active 
role in preserving the DAAO activity through the formation of a protein 
corona able to protect the enzyme from the denaturation processes caused 
by the temperature increase. The next experiments will be conducted in 
order to characterize the peculiar dNP-DAAO protein corona. Once injected 
into the blood stream, the dNP-DAAO will be covered by many different 
biomolecules that finally give a specific fingerprint to the NP that will be 
used by the cells to define their fate. 
 
Cell viability test  
The efficacy of the dNP-DAAO was tested on different cell lines (Fig. 24). The 
overall results for all the concentration tested indicate that, without the 
substrate (D-Ala), the dNP-DAAO toxicity is similar to those of DAAO alone in 
each cell line. When D-Ala is added, the H2O2 produced by both dNP-DAAO 
and DAAO causes cell death. The dNP-DAAO exert a higher cytotoxic effect 
compared to DAAO alone that is dependent by the mU of enzyme present 
into the plate well. This is probably due to the tendency of dNP-DAAO to 
sediment at the bottom of the well where the consequent H2O2 production 
is localized near to the cells enhancing its toxicity. The maximum toxicity of 
dNP-DAAO occurs at 7 mU on all the three tumor cell lines; however, on 
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hASCs, a complete cell death is not fully reached even at 14 mU, leaving 
2.5% of cells alive. These results, together with the ones observed at 3.5 mU 
for both dNP-DAAO and DAAO, could reflect a higher tolerance of hASCs 
toward the oxidative stress caused by H2O2. In fact, it was observed that 
hASCs have a strong antioxidant activity given by the secretion into the cell 
culture media of SOD2168 that reduces the toxicity induced by oxidative 
stress. 
 
 
Fig.24: Cell viability is expressed as a percentage of ATP content after 24 h 
exposure to 3.5, 7 and 14 mU of dNP-DAAO and stock DAAO, with and without the 
substrate D-Ala 1 mM. 
 
Although tumor cells of all the three cell lines were completely killed by 
dNP-DAAO with D-Ala, the human Adipose Stem Cells (hASCs) showed a 
certain grade of tolerance to H2O2. In a wider view, these results could be 
helpful to understand the processes at the base of the higher resistance to 
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oxidative stress presented by cancer stem cells169. Furthermore, from the 
cytotoxicity tests it can be highlighted the lack of target specificity of the 
dNP-DAAO toxicity: though this could be seen as a weak point, it gives the 
possibility to kill a huge variety of cell types through the NPs magnetic 
targeting towards the tissue of interest. Hence, this system could represent 
a very versatile tool to track (through MRI), target and kill tumor cells. 
 
Comparison between the dNP-DAAO and cNP-DAAO systems 
DLS and DCS analysis of the cNP-DAAO system were acquired and eventually 
compared to dNP-DAAO in Tab. 5. 
 
Tab. 5: Comparison between the DCS and DLS analysis of dNP-DAAO (light green) 
and cNP-DAAO (light red) systems 
 
 
As the Tab. 5 shows, the two systems are completely different. DLS and DCS 
analysis together indicate that the cNP-DAAO system is unstable in H2O 
MilliQ as attested by the presence of a wide aggregation process. Although 
the dNP-DAAO system was successfully characterized in the same H2O 
MilliQ, further analysis will be performed in different buffer solutions to 
assess the true characterization of the cNP-DAAO system.  
The comparison of the DAAO binding efficiency between the two NP-DAAO 
systems is reported in Tab. 6. The dNP-DAAO were able to load up to 7.1 
more DAAO than the cNP-DAAO. The yield and activity recovery remain 
unchanged for both the NP-DAAO system. The Units of DAAO found on dNP-
DAAO are about 6.9 times more than the ones present on cNP-DAAO, these 
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results are coherent with the previous results of DAAO loading per mg of 
NPs116. However, according to Cappellini et al116, the cNP-DAAO synthesized 
by us showed different Units per mg of NPs. This fact can be explained by 
the lower enzymatic activity of our RgDAAO stock batches. 
 
Tab.6: Comparison of the DAAO binding efficiency between the cNP-DAAO (light 
red) and dNP-DAAO (light green) systems. 
 
 
The last aspect that was compared between these two systems was their 
intrinsic cytotoxicity (Fig.25). The cytotoxicity exerted on the SKOV-3 cell line 
by the dNP-DAAO is extremely low if compared to cNP-DAAO. However, 
when D-Ala is added both the systems show similar results though the dNP-
DAAO at 3.5 mU result less toxic than cNP-DAAO. This is due to the higher 
intrinsic toxicity of the cNP-DAAO that can be summed to the oxidative 
stress caused by the H2O2 production. These results obtained on SKOV-3 cell 
line are almost identical to U87 and HCT-116 cell lines (data not shown). 
Notwithstanding the fact that dNP-DAAO are better than cNP-DAAO 
regarding the overall aspects assayed, the smaller size and the γ-Fe2O3 core 
composition of dNP-DAAO render them less susceptible to the influence of 
magnetic fields170. Therefore, this characteristic has to be taken in 
consideration when the NPs will be injected in the blood stream because it 
will be difficult to target the dNP-DAAO towards the tissue of interest. 
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Fig. 25: Cytotoxicity of both cNP-DAAO and dNP-DAAO systems on SKOV-3 cell line. 
Cytotoxicity was performed in presence / absence of the substrate D-Alanine (D-
Ala) 1 mM. 
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We have synthesized and analyzed a magnetic NP-enzyme system for cancer 
therapy: dNP-DAAO. Under our best experimental condition, we have 
successfully immobilized up to 446 µg of RgDAAO enzyme per mg of NPs, 
obtaining a yield of 100%, more than 90% of the enzymatic activity recovery 
and finally a DAAO enzymatic activity of 24 U/mg of NPs.  
The dNP-DAAO system characterization by TEM, DLS, DCS and Z-potential 
techniques indicated overall system stability.  
The dNP-DAAO incubated at 37 °C showed a higher enzymatic activity than 
the DAAO alone. Furthermore, the presence of human serum in the 
incubation solution seems to slightly preserve over the time the DAAO 
enzymatic activity. 
The in vitro cytotoxicity tests on different cell lines demonstrated an 
increased efficacy of dNP-DAAO compared to DAAO alone. 
The dNP-DAAO system was partially compared to the one (cNP-DAAO) 
obtained from the Cappellini et al116 procedure, showing three main 
remarkable improvements: 
- A higher amount of DAAO loaded up to 7 times more due to the 
smaller size and the consequent higher surface area of the dIONPs 
compared to cIONPs. 
- A better system stability in aqueous solution given by DLS and DCS 
analysis. 
- A lower intrinsic toxicity of the system given by the reduced amount 
of NPs required for the same DAAO enzymatic activity. 
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Future aims will be to evaluate:  
- The magnetic properties of the dNP-DAAO system.  
- The role of the protein corona in dNP-DAAO activity, kinetic 
properties and cellular uptake. 
- The dNP-DAAO biodistribution through the body with/without an 
eternal magnetic field with particular care of the ability to cross 
blood-barriers. 
- The dNP-DAAO efficacy in destroying cancer cell in in vivo 
experiments. 
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CHAPTER III - SYNTHESIS OF 
MAGNETIC NP-ENZYME SYSTEM FOR INDUSTRY: 
THE NP-LASPO SYSTEM 
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Enzyme 
The L-Aspartate oxidase (LASPO) used is this work is the wild type from 
Sulfolobus tokodaii that was overexpressed in E. coli cells and purified to > 
95% purity as described by Bifulco et al130. The purified batch of StLASPO 
(2,255U/mL; 0,37U/mg) was stored in 20 mM Tris–HCl buffer at pH 7.5 and 
10% glycerol. The LASPO enzyme was provided by the laboratory of Prof. 
Loredano Pollegioni of the Biotechnology and Life Sciences Department of 
Università degli Studi dell'Insubria, Varese. 
 
IONPs and IO-APTES NPs 
The Iron Oxide Nanoparticles (IONPs) and the functionalized IO-APTES NPs 
(NP-APTES) were the same commercial NPs (cIONPs and cNP-APTES) used 
for the synthesis of the cNP-DAAO system (see the “Material and Methods” 
section in “Chapter II”). 
 
IO-APTES-LASPO (NP-LASPO) 
According to a protocol previously developed in our laboratory, 4 mg of NP-
APTES were ultrasonicated for 15 min in NaPPi buffer 5 mM pH 8.0, then 6 
mg of EDC (1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide, Sigma n.cat: 
03450) and 8 mg of NHS (N-Hydroxysuccinimide, Sigma, n.cat: 130672) were 
added under sonication. Then, 100 μg of LASPO were added and NaPPi 
buffer 5 mM pH 8.0 up to a final reaction volume of 1 mL. The reaction was 
carried out for 2 h at room temperature on a rotating plate tube stirrer. 
Subsequently, NP-LASPO were collected using a magnet and washed twice 
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with 1 mL of NaPPi 5 mM pH 8.0. The supernatant was stored for further 
analysis. 
These conditions of reaction represented the starting point of the 
optimization process done in this work. In order to establish the best 
conditions for LASPO conjugation to NP-APTES, four main parameters were 
considered: pH, NP-APTES amount, EDC:NHS concentration/ratio and 
reaction time. In the Tab. 7 the conditions at which the reactions were 
carried out are indicated.  
 
Tab. 7: Different conditions for the LASPO conjugation reaction: the modified 
parameters for each reaction are indicated in bold. 
NP-APTES (mg) LASPO (μg) EDC:NHS EDC (mg) pH Time (h) 
8 100 3:2 6 8.0-9.0 2 
4 
100 3:2 6 8.5 2 
5 
6 
7 
8 
4 100 3:2 
6 
8.5 2 5 4 
3 
4 100 1:1 
3 
8.5 2 4 
6 
4 100 2:3 
4 
8.5 2 3.3 2.7 
2 
4 100 2:3 2 8.5 
0.5 
1 
1.5 
2 
2.5 
4 
III.I   MATERIALS AND METHODS 
73 
At the end of each series of conjugation reactions, the best condition 
(reflected by the higher activity recovery) was used as the starting point for 
the next optimization step. 
 
NP-LASPO Enzyme Activity Assay 
The NP-LASPO activity was assayed by measuring the initial rate of 
production of H2O2 with a coupled peroxidase/dye assay. The H2O2 reacts 
with phenol and 4-aminoantipyrine (4-AAP) by the catalytic action of 
peroxidase to form a red colored quinoamine dye complex. The dye 
produced was detected with a spectrophotometer at 505 nm (ε = 6.58 mM-
1 cm-1) and 25 °C. According to Bifulco et al. 130, the standard assay mixture 
contained: 50 mM of Sodium Pyrophosphate, 1.5 mM 4-AAP, 2 mM Phenol, 
20 μM FAD (flavin adenine dinucleotide), 10 mM L-Aspartate, 2.5 U of POD 
(horseradish peroxidase), in a final volume of 1mL. 40µl of NP-LASPO were 
assayed with a fixed wavelength measurement: the blank was read at λ=505 
nm, NP-LASPO were added and incubated for 5 minutes at RT. Then, NP-
LASPO were collected with the magnet and the supernatant was read. 
 
NP-LASPO Yield and Activity Recovery 
The yield and the activity recovery of each different NP-LASPO conjugation 
reaction were calculated as previously described for the NP-DAAO (see the 
“Material and Methods” section in “Chapter II”). 
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pH range  
Several reactions were carried out to evaluate the effect of pH on the 
immobilization St-LASPO, varying the pH range from 8.0 to 9.0 (Tab. 8).  
 
Tab. 8: Yield and activity recovery of the conjugation reactions performed at 
different pH. The best condition is indicated in underlined bold. 
pH Yield (%) Activity Recovery (%) 
8 99.7 37.5 
8.1 99.7 30.1 
8.3 99.6 37.2 
8.5 99.9 43.5 
8.7 99.6 34.0 
8.9 99.5 30.0 
9 99.4 42.1 
 
The data suggest that the best reaction was the one conducted at pH 8.5 as 
shown by both the yield and the activity recovery. 
 
NP-APTES amount  
NP-APTES at different concentrations were tested on the updated reactions 
at pH 8.5 (Tab. 9). 
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Tab. 9: Yield and activity recovery of the updated conjugation reaction performed 
with different amount (mg) of NP-APTES. The best condition is indicated in 
underlined bold. 
NP-APTES (mg) Yield (%) Activity Recovery (%) 
4 74.7 125.4 
5 54.5 85.9 
6 49.0 82.4 
7 63.7 63.9 
8 99.9 43.5 
 
From the reaction results listed in Tab. 9, the best activity recovery was 
obtained by using 4 mg of NP-APTES whilst the best yield with 8 mg. 
Although the yield, the best conjugation reaction was carried out with 4 mg 
of NP-APTES as reported by the highest activity recovery. Hence, since the 
yield is lower than the activity recovery, we can assume that the LASPO 
immobilized possess a higher enzymatic activity compared to free one. 
 
Amount and ratio of EDC:NHS 
Different concentrations and ratio of EDC and NHS were assayed during the 
enzyme conjugation reaction at pH 8.5 with 4 mg of NP-APTES (Tab. 10). The 
ratio of EDC:NHS was also subdivided in the molarity of each single chemical 
to have a better idea of the total moles occurring in the reaction. 
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Tab. 10: Yield and activity recovery of the updated conjugation reaction performed 
with different amount (mg) and ratio EDC:NHS (the w/w is expressed in mg). The 
molarity of both the EDC and NHS in the reaction is reported respectively in the 
second and third column. The best condition is indicated in underlined bold. 
EDC:NHS (w/w)  EDC (mM) NHS (mM) Yield (%) Activity Recovery (%) 
6/4 39 35 74.7 125.4 
5/3,3 32 29 90.7 70.7 
4/2,7 26 23 94.5 81.6 
3/2 19 17 87.8 105.4 
3/3 19 26 88.1 116.3 
4/4 26 35 81.3 124.4 
6/6 39 52 77.5 119.4 
4/6 26 52 93.6 87.0 
3,3/5 21 43 80.9 106.5 
2,7/4 17 35 85.7 113.1 
2/3 13 26 85.6 134.6 
 
The results show that the best condition for the LASPO conjugation was 
reached by using 2 mg of EDC and 3 mg of NHS per reaction. Looking at the 
molar ratio of the best reaction condition, the number of the NHS moles has 
to be double the EDC ones.   
 
Reaction time  
To check the optimum time needed for the LASPO conjugation onto NP-
APTES, the reactions were conducted from 30 to 240 minutes (Tab. 11). 
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Tab. 11: Yield and activity recovery of the updated conjugation reaction carried out 
at different times. The best condition is indicated in underlined bold. 
Time (min) Yield (%) Activity Recovery (%) 
30 83.8 70.4 
60 84.3 84.0 
90 84.9 82.7 
120 85.6 134.6 
150 85.5 95.0 
240 78.6 99.0 
 
The results reported in Tab. 11 confirm that the best condition of reaction 
was the one already used in the previous method, namely at 120 minutes. 
 
The case of the enzymatic activity increase  
The final activity recovery suggests that, despite the decrease of the yield, 
the LASPO immobilized presents a higher activity: indeed, as previously 
reported, enzymes conjugated to NPs may present an enhanced activity, a 
better specificity, a prolonged half-life, an enhanced thermal stability and, in 
some cases, even an enzymatic acceleration89,171,172. 
Studying NP-enzyme conjugates, Ding et al89 identified five physicochemical 
mechanisms that most contribute to higher the enzymatic activity:  
1- A higher enzyme density;  
2- An enhanced mass transport of incident substrate due to the 
attraction of substrate to the NP-enzyme surface as well as to the 
movement of the NP–enzyme complex; 
3- The NP curvature/morphology and surface chemistry;  
4- The NP surface chemistry;  
5- A favourable enzyme orientation leading to an increased the 
enzyme–substrate interactions; 
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Several reactions were performed to reach the best condition for LASPO 
conjugation to NP-APTES. In Fig. 26 each optimization step occurred from 
the starting NP-LASPO conjugation protocol is summarized.  
 
 
Fig. 26: Optimization steps from the starting NP-LASPO conjugation protocol to the 
final improved one. 
 
Among the four parameters analysed, only the reaction time confirmed its 
validity remaining stable at 2 hours. However, the updated optimal 
conjugation protocol switched the reaction pH from 8.0 to 8.5, the amount 
of NP-APTES from 8 mg to 4 mg and finally the EDC:NHS amount (mg) and 
ratio from 6:4 to 2:3. 
The overall percentages of yield and activity recovery of the optimized 
conjugation protocol are respectively the 85.6% and the 134.6%: if these 
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values are normalized to those of the starting conjugation protocol, we 
obtain correspondingly the 85.7% and the 359%. 
In biocatalysis, the susceptibility of the NP-LASPO to a magnetic field would 
allow its efficient recovery enabling also the reuse for several times and 
prevention of the final products contamination. 
 
Future goals will be to repeat the experiments with different StLASPO 
batches in order to confirm the results. The kinetic properties of the 
immobilized enzyme will be characterized investigating via HPLC analysis the 
range of temperature and pH with higher performances in terms of activity 
and stability. Moreover, it will be checked the NP-LASPO ability to resolve 
racemic solution of D,L-Aspartate. Finally, it will be investigated the 
mechanisms that cause the enhanced enzymatic activity of the immobilized 
LASPO.
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hASCs isolation and culture 
hASCs were isolated from mammary adipose tissue after surgical 
intervention due to breast hypertrophy (gigantomastia). The stromal cellular 
fraction, obtained according to Gronthos & Zannettino protocol173, was 
seeded in T75 flask with 15 mL of cell culture medium and, after 6 h, the 
medium was replaced with the fresh one in order to remove unattached 
cells.  
The hASCs cell culture medium was a 1:1 DMEM/DMEM-F12 supplemented 
with 10% fetal bovine serum (FBS), 1% L-Glutamine, 1% 
penicillin/streptomycin solution, 0.1% gentamicin and 0.04% fungizone. 
hASCs were passaged as needed using a solution at 0.25% trypsin–EDTA. 
 
hASCs characterization by flow cytometry 
The cell surface phenotype was assessed by flow cytometry analysis using a 
FACSAria II apparatus (BD, NJ, USA). To typify the hASCs population, a series 
of monoclonal antibodies (mAb) was used against the following specific cell 
surface markers: CD44, CD90, CD105 as a nominal staminal markers, CD45 
as a differentiation marker and lastly HLA-A,B,C and HLA-DR respectively to 
check the HLA class I and class II molecules of the major histocompatibility 
complex. Anti-CD44, -CD45, -CD105 mAbs were fluorescein isothiocyanate 
(FITC) labeled whilst anti-CD90 was phycoerythrin (PE) labeled. Anti-HLA 
class I and class II mAbs were unlabeled and revealed by second-step 
incubation with goat antimouse IgG FITC-labeled. After antibody staining, 
cells were washed with PBS at 4 °C and fixed with 150 μL of PBS 4% 
paraformaldehyde for 30 min before the flow cytometry analysis. 
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Nanoparticles 
The zerovalent nanoparticles (NPs) of Cobalt (CoNPs), Iron (FeNPs) and 
Nickel (NiNPs) were purchased from American Elements (Los Angeles, CA, 
USA):  
? FeNPs: Product Code: FE-M-03M-NP.025N CAS #: 7439-89-6 APS*: ?25nm; 99.9% purity. 
? NiNPs: Product Code: NI-M-03M-NP.020N CAS #: 7440-02-0 APS*: ?20nm; 99.8% purity. 
? CoNPs: Product Code: CO-M-0251M-NP.030N CAS #: 7440-48-4 
APS*: ?30nm; 99.5% purity. 
*APS = Aerodynamic Particle Sizer 
 
Cell viability test 
In 96-well plates about 1000 hASCs were seeded and cultivated for 24 h at 
37 °C in 5% CO2 to equilibrate and become attached prior the treatment. 
Then, the cells were exposed for 24, 48, 72 and 96 h to increasing amount of 
NPs (0.3125 - 100 µg) resuspended in a final medium volume of 200 µL. NPs 
were previously ultrasonicated with the Ultrasonic Cleaner M S3 (Soltec, 
Milan, Italy) for at least 20 minutes to break any NPs agglomerates. Cell 
viability was determined by measuring cellular ATP content using the 
CellTiter-Glo Assay (Promega, Milan, Italy). The procedure is the same 
previously reported in the “Cell viability test” paragraph of the “Materials 
and methods” in Chapter II. 
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Adipogenic differentiation after hASCs exposure to CoNPs and CoCl2 
1000 cells were seeded on coverslips placed in a 6-well plate and left in the 
cell incubator for 24 h at 37 °C in 5% CO2. Then, hASCs were treated with 2 
mL of CoNPs 4.6 µg/mL and observed after 4, 7 and 10 days with an Inverted 
Contrast-Phase Microscope (ICPM) and an optical microscope respectively 
prior and after the cell staining. To highlight lipid droplets, cells were fixed 
and stained with Oil Red O (Sigma-Aldrich, Milan, Italy). 
Moreover, since it happens that some types of NPs can dissolve into the 
culture medium, the experiment was carried out in parallel by using the 
same concentration of the corresponding Cobalt salt (CoCl2). This helped to 
discriminate if the differentiation effect was due to CoNPs instead of CoCl2. 
The employed concentration of CoNPs was assumed by the result of the 
cytotoxicity assay also keeping in consideration that each of the used NPs 
tends to precipitate to the bottom of the well plate. Consequently, the final 
CoNPs concentration used for this test was calculated by normalizing the 
amount of µg NPs on the total surface area of the well (0.32 cm2 per well in 
a 96-well plate and 9.4 cm2 per well in a 6-well plate). Hence, the 2 mL of 
CoNPs 4.6 µg/mL resulted in about 0.94 µg of CoNPs per cm2 of well surface 
that correspond to the lowest amount of CoNPs tested in the cell viability 
assay. 
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hASCs characterization 
After hASCs isolation from adipose tissue, their phenotype was assessed 
firstly by their morphological aspects and secondly by the presence of 
specific cell surface markers with flow cytometry. 
The picture of hASCs acquired by ICPM (Fig. 27) shows the typical spindle-
shaped fibroblast-like morphology as also observed in some previous 
studies174–176. 
 
 
Fig. 27: hASCs morphology with the typical spindle-shaped fibroblast-like aspect. 
The picture was acquired by an Inverted Contrast-Phase Microscope (ICPM) 
 
The flow cytometry analysis (Fig. 28) reports that hASCs, similarly to the 
mesenchymal stem cells (MSCs) isolated from other tissues, expressed the 
CD44, CD90 and CD105 surface markers but not the CD45 that, indeed, is 
expressed on endothelium as well as on leukocytes. Moreover, the hASCs 
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population positively expressed the HLA-A,B,C surface molecules but not the 
HLA-DR one.  
 
 
Fig. 28: hASCs immunophenotype from flow cytometry assays. The specific 
fluorescence is represented by the bold histogram; the dashed histogram is the 
negative control of the unlabelled isotypes. In the abscissa the mean fluorescence 
in arbitrary unit (a.u.) is reported whilst in the ordinate the number of analyzed 
cells. 
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This peculiar cellular immunophenotype, where the CD44, CD90, CD105 and 
HLA-A,B,C are positively expressed whilst the CD-45 and HLA-DR are not, 
confirmed the stemness of the isolated hASCs population utilized in this 
study. Furthermore, this immunophenotype is observed in many studies174–
178.  
 
Cell viability 
The cell viability assay was performed on hASCs exposed to an increasing 
amount (0.3125 – 100 µg) of CoNPs, FeNPs and NiNPs for up to 96 h. The cell 
viability results (Fig. 29) show a dose and time dependent toxicity for both 
CoNPs and NiNPs whilst only dose dependent for FeNPs: the more cytotoxic 
NPs were the NiNPs followed by CoNPs and lastly by FeNPs. The cytotoxicity 
of NiNPs and CoNPs at between 20 – 100 µg was very similar even though at 
the lower range (0.3125 – 10 µg) it appeared to be slightly different. 
Although the toxicity exerted by FeNPs on hASCs was more due to the dose 
instead of the time of exposure, they did not report a complete cell death 
also at the highest dose tested. These results partially fit with those of 
literature179 conducted on different cell lines. 
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Fig. 29: Viability assay shows that cell viability is dose and time dependent for both 
CoNPs and NiNPs whilst only dose dependent for FeNPs. Error bars refer to the 
standard deviation among three tests. 
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Adipogenic differentiation after hASCs exposure to CoNPs and CoCl2 
The results obtained from cell viability assay with CoNPs were used to get 
the suitable concentration to perform the first of the hASCs Adipogenic 
differentiation test. Thus, it was chosen the concentration of 4.6 µg/mL (see 
“Material and Methods”), that correspond to the lowest amount of CoNPs 
tested in the cell viability assay, to lead hASCs up to 10 days without an 
excessive cell death.  
Since it has been proved that CoNPs can dissolve into the culture media 
releasing ions179,180, in parallel with the NPs treatment, it was also assayed 
the differentiation potential of CoCl2 at the same concentration. 
After 4 days of cell exposure to Cobalt, both NPs and ions revealed a low 
cytotoxicity accompanied by the beginning of the Adipogenic differentiation 
process as shown by the lipid droplets (Fig. 30a) highlighted after the ORO 
staining. These lipid droplets, always absent in the control hASCs, increased 
from day 4 to day 10 in the treated hASCs (Fig. 30b-c). However, after 10 
days of exposure to Cobalt, the cell viability was greatly reduced and the 
presence of several vacuoles suggested the activation of the apoptotic 
processes.  
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Fig. 30: hASCs Adipogenic differentiation after 4(a), 7(b) and 10(c) days of Cobalt 
exposure. Red arrows indicate the CoNPs while the yellow ones the lipid droplets, 
clearly visible after Oil Red O staining. The presence of several vacuoles (green 
arrows) is probably a sign of an apoptotic process. Inverted phase-contrast 
microscope (IPCM); optic microscope (OM). 
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These preliminary results demonstrate the Cobalt capability, without 
distinction among CoNPs and CoCl2, to differentiate hASCs into 
preadipocytes. Nevertheless, the concentration of Cobalt used was too high 
inducing an extensive cell death.  
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Since the NP applications are exponentially growing, we have to be aware 
about their safety or not. We chose to perform the experiments with stem 
cells because they play a key role in our life and the possible perturbation of 
their homeostasis could be very harmful. Hence, in the last part of this work 
we started to investigate the in vitro NP toxicity using a subgroup of MSCs 
extracted from human adipose tissue, named hASCs, as a cell-line model 
because of their many advantages compared to other stem cell (see the 
“Adipose Stem Cell (ASCs)” section in “Chapter I”). 
In this study a hASCs population was effectively isolated, as shown by the 
morphological and the flow cytometry characterization. The in vitro 
stemness of this MSCs population was proved by the positivity to CD44, 
CD90, CD105 and HLA-A,B,C and negativity to CD45 and HLA-DR. 
Furthermore, the cytotoxicity of CoNPs, FeNPs and NiNPs was assayed on 
hASCs: CoNPs and NiNPs exert a higher cytotoxic effect, which is also dose 
and time dependent, than FeNPs, only dose dependent.  
Finally, the possible hASCs adipogenic differentiation induced by CoNPs was 
evaluated. The morphological analysis pointed out that both CoNPs and 
CoCl2 were able to speed up the differentiation process even though in this 
experimental condition the mortality was rather high. These are preliminary 
results and we need to investigate in more detail if this process is due to 
CoNPs or Co2+ ions or both these components.  
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Future aims will be to assess deeper each experimental step carried out in 
this study: 
1. We have to verify the in vivo hASCs stemness by exposing them to an 
appropriate growing media added with hormones/molecules able to 
differentiate them toward the different cellular lineages. Each step 
will be investigated through both Real-time PCR and differential 
staining by using specific molecular markers. 
2. We will perform the NPs dissolution assays also in hASCs plating 
medium (DMEM:DMEM-F12) to know whether and how many ions 
can be released into the medium. Later on we will assay how this 
process is relevant for the overall toxicity and differentiation 
processes; then we will compare the NPs toxicity to that of their 
corresponding salts. 
3. We will set up differentiation tests also for NiNPs and FeNPs and 
their relative salts. During NPs-induced differentiation process each 
passage will be followed by the analysis of the telomerase activity, 
the length of telomeres and the eventual mutation of P53. 
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